参考文献
[1] Konstam MA, Kramer DG, Patel AR, et al. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment[J]. JACC Cardiovasc Imaging, 2011,4(1):98-108. DOI: 10.1016/j.jcmg.2010.10.008.
[2] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南 2018[J]. 中华心血管病杂志 ,2018,46(10):760-789.DOI: 10.3760/cma.j.issn.0253-3758.2018.10.004.
[3] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC)Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J, 2016,37(27):2129-2200. DOI: 10.1093/eurheartj/ehw128.
[4] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol,2013,62(16):e147-e239. DOI:10.1016/j.jacc.2013.05.019.
[5] Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling[J]. J Am Coll Cardiol, 2000,35(3):569-582. DOI: 10.1016/s0735-1097(99)00630-0.
[6] Yalta K, Yilmaz MB, Yalta T, et al. Late versus early myocardial remodeling after acute myocardial infarction: a comparative review on mechanistic insights and clinical implications[J]. J Cardiovasc Pharmacol Ther, 2020,25(1):15-26. DOI: 10.1177/1074248419869618.
[7] Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left ventricular systolicdysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance[J]. Am J Cardiol, 2006,97(10A):13F-25F. DOI: 10.1016/j.amjcard.2006.03.005.
[8] Kelly DJ, Gershlick T, Witzenbichler B, et al. Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial[J]. Am Heart J, 2011,162(4):663-670. DOI: 10.1016/j.ahj.2011.08.002.
[9] Bolognese L, Neskovic AN, Parodi G, et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications[J]. Circulation, 2002,106(18):2351-2357. DOI: 10.1161/01.cir.0000036014.90197.fa.
[10] Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling:mechanisms: part 1 of 2[J]. Circulation, 2013,128(4):388-400. DOI: 10.1161/CIRCULATIONAHA.113.001878.
[11] Huttin O, Coiro S, Selton-Suty C, et al. Prediction of left ventricular remodeling after a myocardial infarction: role of myocardial deformation: a systematic review and meta-analysis[J]. PLoS One,2016,11(12):e0168349. DOI: 10.1371/journal.pone.0168349.
[12] Zaliaduonyte-Peksiene D, Simonyte S, Lesauskaite V, et al. Left ventricular remodelling after acute myocardial infarction: impact of clinical, echocardiographic parameters and polymorphism of angiotensinogen gene[J]. J Renin Angiotensin Aldosterone Syst, 2014,15(3):286-293. DOI: 10.1177/1470320312471228.
[13] Tarantini G, Napodano M, Gasparetto N, et al. Impact of multivessel coronary artery disease on early ischemic injury, late clinical outcome, and remodeling in patients with acute myocardial infarction treated by primary coronary angioplasty[J]. Coron Artery Dis, 2010,21(2):78-86. DOI: 10.1097/MCA.0b013e328335a074.
[14] Aplin M, Kyhl K, Bjerre J, et al. Cardiac remodelling and function with primary mitral valve insufficiency studied by magnetic resonance imaging[J]. Eur Heart J Cardiovasc Imaging, 2016,17(8):863-870. DOI: 10.1093/ehjci/jev321.
[15] 丁丹 , 王雪臣 , 李庆海 . 冠状动脉慢性完全性闭塞患者经皮冠状动脉介入治疗前后左心室功能和心脏重构指标的变化分析 [J]. 中华实用诊断与治疗杂志 ,2019,33(4):343-346. DOI: 10.13507/j.issn.1674-3474.2019.04.009.
[16] Sigusch HH, Campbell SE, Weber KT. Angiotensin Ⅱ-induced myocardial fibrosis in rats: role of nitric oxide, prostaglandinsand bradykinin[J]. Cardiovasc Res, 1996,31(4):546-554.
[17] Cokkinos DV, Belogianneas C. Left ventricular remodelling: a problem in search of solutions[J]. Eur Cardiol, 2016,11(1):29-35. DOI: 10.15420/ecr.2015:9:3.
[18] Marino R, Magrini L, Orsini F, et al. Comparison between soluble ST2 and high-sensitivity troponinⅠ in predicting short-term mortality for patients presenting to the emergency department with chest pain[J]. Ann Lab Med, 2017,37(2):137-146. DOI: 10.3343/alm.2017.37.2.137.
[19] Bayes-Genis A, de Antonio M, Galán A, et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure[J]. Eur J Heart Fail, 2012,14(1):32-38. DOI: 10.1093/eurjhf/hfr156.
[20] Azevedo PS, Polegato BF, Minicucci MF, et al. Cardiac remodeling: concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment[J]. Arq Bras Cardiol, 2016,106(1):62-69. DOI: 10.5935/abc.20160005.
[21] Weiner RB, Baggish AL, Chen-Tournoux A, et al. Improvementin structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the proBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study[J]. Eur J Heart Fail, 2013,15(3):342-351. DOI: 10.1093/eurjhf/hfs180.
[22] Van de Werf F, Bax J, Betriu A, et al. Management of acutemyocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology[J]. Eur Heart J, 2008,29(23):2909-2945. DOI: 10.1093/eurheartj/ehn416.
[23] Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee forpractice guidelines: the Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology(ESC)[J]. Eur Heart J, 2016,37(36):2768-2801. DOI: 10.1093/eurheartj/ehw211.
[24] Lang RM, Bierig M, Devereux RB, et al. Recommendationsfor chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology[J]. J Am Soc Echocardiogr, 2005,18(12):1440-1463. DOI: 10.1016/j.echo.2005.10.005.
[25] Bhatt AS, Ambrosy AP, Velazquez EJ. Adverse remodeling and reverse remodeling after myocardial infarction[J]. Curr Cardiol Rep, 2017,19(8):71. DOI: 10.1007/s11886-017-0876-4.
[26] Fieno DS, Kim RJ, Chen EL, et al. Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing[J]. J Am Coll Cardiol, 2000,36(6):1985-1991. DOI: 10.1016/s0735-1097(00)00958-x.
[27] Tarantini G, Razzolini R, Cacciavillani L, et al. Influence of transmurality, infarct size, and severe microvascular obstruction on left ventricular remodeling and function after primary coronary angioplasty[J]. Am J Cardiol, 2006,98(8):1033-1040. DOI: 10.1016/j.amjcard.2006.05.022.
[28] Beller GA, Heede RC. SPECT imaging for detecting coronary artery disease and determining prognosis by noninvasive assessment of myocardial perfusion and myocardial viability[J]. J Cardiovasc Transl Res, 2011,4(4):416-424. DOI: 10.1007/s12265-011-9290-2.
[29] Hsiao JF, Chung CM, Chu CM, et al. Two-dimensional speckle tracking echocardiography predict left ventricular remodeling after acute myocardial infarction in patients with preserved ejection fraction[J]. PLoS One, 2016,11(12):e0168109. DOI: 10.1371/journal.pone.0168109.
[30] Echouffo-Tcheugui JB, Erqou S, Butler J, et al. Assessing the risk of progression from asymptomatic left ventricular dysfunction to overt heart failure: a systematic overview and meta-analysis[J]. JACC Heart Fail, 2016,4(4):237-248. DOI: 10.1016/j.jchf.2015.09.015.
[31] Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart[J]. N Engl J Med, 1997,336(16):1131-1141. DOI: 10.1056/NEJM199704173361603.
[32] Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators[J]. N Engl J Med, 1992,327(10):669-677. DOI: 10.1056/NEJM199209033271001.
[33] CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)[J]. N Engl J Med, 1987,316(23):1429-1435. DOI: 10.1056/NEJM198706043162301.
[34] Tepper D. Frontiers in congestive heart failure: beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction[J]. Congest Heart Fail, 1999,5(3):131-132.
[35] Montalescot G, Pitt B, Lopez de Sa E, et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study[J]. Eur Heart J, 2014,35(34):2295-2302. DOI: 10.1093/eurheartj/ehu164.
[36] Lax A, Sanchez-Mas J, Asensio-Lopez MC, et al. Mineralocorticoidreceptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction[J]. JACC Heart Fail, 2015,3(1):50-58. DOI: 10.1016/j.jchf.2014.07.015.
[37] Hajra A, Ujjawal A, Sud K, et al. Sacubitril/Valsartan averts post-myocardial infarction ventricular remodeling and preserves heart function[J]. Int J Cardiol Heart Vasc, 2019,22:218-219. DOI: 10.1016/j.ijcha.2019.02.005.
[38] Desai AS, Solomon SD, Shah AM, et al. Effect of SacubitrilValsartan vs Enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial[J]. JAMA, 2019:1-10. DOI: 10.1001/jama.2019.12843.
[39] Januzzi JL, Butler J, Fombu E, et al. Rationale and methods of the prospective study of biomarkers, symptom improvement, and ventricular remodeling during Sacubitril/Valsartan therapy for heart failure (PROVE-HF)[J]. Am Heart J,2018,199:130-136. DOI:10.1016/j.ahj.2017.12.021.
[40] Martens P, Nuyens D, Rivero-Ayerza M, et al. Sacubitril/Valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction[J]. Clin Res Cardiol, 2019,108(10):1074-1082. DOI: 10.1007/s00392-019-01440-y.
[41] U.S. National Library of Medicine. Prospective ARNI vs ACE inhibitor trial to determine superiority in reducing heart failure events after MI (PARADISE-MI)[EB/OL]. (2020-08-05)[2020-08-10]. https://clinicaltrials.gov/ct2/show/NCT02924727.
[42] Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure)[J]. J Am Coll Cardiol, 2005,46(6):e1-e82. DOI: 10.1016/j.jacc.2005.08.022.
[43] Scirica BM, Morrow DA, Cannon CP, et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study[J]. J Am Coll Cardiol, 2006,47(11):2326-2331. DOI: 10.1016/j.jacc.2006.03.034.
[44] Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction[J]. N Engl J Med, 2002,346(12):877-883. DOI: 10.1056/NEJMoa013474.